IDEA Collider: Innovation & Asymmetric Learning in Pharma

Building the Future of Targeted Protein Degradation Medicines with Nello Mainolfi
In this episode of IDEA Collider, host Mike Rea sits down with Nello Mainolfi, founder and CEO of Kymera Therapeutics. Nello shares his journey from medicinal chemist to biotech founder and discusses the opportunities and lessons learned from building a company at the forefront targeted protein degradation. Episode Timestamps; 00:00 Welcome to Idea Collider 00:18 Kymera 2026 Catalysts 02:33 De Risking with Degraders 02:54 Targeted Protein Degradation 101 06:20 KT-621 STAT6 Degrader 08:16 Rethinking Type 2 Disease Treatment 12:21 Nello’s Path to CEO 16:32 Building a Standalone Biotech 23:19 Partnering with Big Pharma 26:51 Culture and Office Energy 32:03 Capital Plan and Potential Launches 36:24 Belief and Execution Mindset 39:00 Life Outside the Lab 40:07 Where to Follow Kymera 40:35 Closing Thanks Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Nello Mainolfi & Kymera LinkedIn: https://www.linkedin.com/in/nello-mainolfi-2b55421a/ or https://www.linkedin.com/company/kymeratherapeutics/ Website: https://www.kymeratx.com/ Follow IDEA Pharma On; Website: https://www.ideapharma.com/ LinkedIn: https://www.linkedin.com/company/idea-pharma/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
